Drugs / CUSA-081
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03992443 | Feb → Mar 2022 | — | Chiesi Farmaceutici S.p.A. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03594175 | Feb 2020 → Jun 2023 | thrombotic disease, vascular occlusion disorder | Chiesi Farmaceutici S.p.A. | Terminated | Met primary Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUSA-081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03992443 ↗ |
| Known as | Reteplase | “Reteplase” NCT03594175 ↗ |
| Modality | Protein / enzyme biologic | “CUSA-081 (reteplase) is a recombinant tissue plasminogen activator (tPA)” NCT03594175 ↗ |
| Route | Other | “directly into the catheter lumen” NCT03594175 ↗ |